Every material Form 8-K Tvardi Therapeutics, Inc. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tvardi Therapeutics reported a second-quarter 2026 net loss of $6.5 million, compared with net income of $4.2 million a year earlier, which included a $12.7 million non-cash gain. The company also reported topline healthy volunteer results for TTI-109, selected ulcerative colitis as its initial indication, and said its cash runway reaches the HCC readout in the third quarter of 2027, with additional funding needed to advance TTI-109 in UC.
Net loss of $6.5 million for the quarter ended June 30, 2026, versus net income of $4.2 million in the same period of 2025; basic and diluted loss per share was $(0.69).
Research and development expenses fell to $4.0 million from $5.8 million, and general and administrative expenses fell to $2.6 million from $3.1 million.
Cash, cash equivalents and short-term investments were $15.8 million at June 30, 2026, down from $30.8 million at December 31, 2025.
A KOL webinar on TTI-109 in UC is scheduled for August 19, 2026; the UC trial start is planned for 2027, subject to IND clearance and additional funding.
Tvardi Therapeutics said it selected ulcerative colitis (UC) as the initial disease indication for its oral STAT3 inhibitor TTI-109, following a completed Phase 1 healthy volunteer study. The company plans a UC clinical trial in 2027, subject to IND clearance and additional funding, and will host a key opinion leader webinar on August 19, 2026.
Phase 1 healthy volunteer study showed placebo-adjusted reductions in immune cell subsets, including up to 76% reduction in Th17-associated populations.
Company cites an addressable market of approximately $3 billion in the U.S. and $9 billion globally for UC.
Planned UC trial start in 2027 is subject to IND clearance and additional funding, and the company has not stated amounts of additional funding needed.
KOL webinar with Dr. Randy Longman is scheduled for Wednesday, August 19, 2026 at 11:00 AM ET.
Tvardi Therapeutics filed a prospectus supplement on July 17, 2026, raising its at-the-market share sale capacity under its JonesTrading sales agreement by up to $9,689,765. The filing says the company is subject to the SEC's baby shelf rule, which caps sales based on non-affiliate market value, and that no further shares will be sold under the prior prospectus after the supplement date. For shareholders, the expansion signals potential dilution from additional share issuance.
On July 17, 2026, the company filed a prospectus supplement allowing issuance of up to $9,689,765 in shares, in addition to amounts previously sold.
Baby shelf limits apply: non-affiliate market value is $62,208,945, based on 12,441,789 shares at $5.00 on July 8, 2026.
In the prior twelve months, the company sold 3,110,769 shares for about $11.0 million in gross proceeds under the sales agreement.
The Sales Agreement with JonesTrading Institutional Services LLC was entered into on May 1, 2026; Cooley LLP's legal opinion is filed as Exhibit 5.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tvardi Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →